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BACKGROUND: Levofloxacin-based triple therapy has been suggested as an alternative salvage therapy to
bismuth-based quadruple therapy for persistent Helicobacter pylori (H. pylori) infection.
METHODS: A search of PUBMED, EMBASE, EBM Review databases and abstracts from recent Digestive Disease
Week, United European Gastroenterology Week, and European Helicobacter Study Group
conferences was performed. Randomized controlled trials (RCTs) comparing levofloxacin-based
triple salvage therapy (levofloxacin + amoxicillin + PPI) to bismuth-based quadruple salvage
therapy (bismuth + tetracycline + metronidazole + PPI) were selected for meta-analysis.
Additionally, all prospective trials evaluating this levofloxacin-based triple therapy as salvage therapy
were pooled to analyze optimal levofloxacin treatment duration and dosing. All selected trials
confirmed prior treatment failure and post-salvage treatment eradication.
RESULTS: Four RCTs compared a 10-day regimen of levofloxacin-based triple therapy to 7-day bismuth-based
quadruple therapy (n = 391 patients). Levofloxacin-based triple therapy was superior to quadruple
therapy (RR = 1.41 [95% CI: 1.25–1.59]). Levofloxacin-based triple therapy was better tolerated
than quadruple therapy with a lower incidence of side effects (RR = 0.51 [95% CI: 0.34–0.75]) and
side effects prompting discontinuation of therapy (RR = 0.30 [95% CI: 0.10–0.89]). Eleven trials
(n = 547 patients) evaluating levofloxacin-based triple therapy demonstrated higher eradication
rates with 10-day versus 7-day regimen (87% [95% CI: 82%-92%] vs 68% [95% CI: 62%-74%]) yet
eight trials (n = 477 patients) demonstrated no difference with 500 mg daily versus 250 mg b.i.d.
dosing of levofloxacin (81% [95% CI: 78%-89%] vs 84% [95% CI: 66%-97%]).
CONCLUSIONS: A 10-day course levofloxacin triple therapy is more effective and better tolerated than 7-day
bismuth-based quadruple therapy in the treatment of persistent H. pylori infection.
(Am J Gastroenterol 2006;101:488–496)
INTRODUCTION
Helicobacter pylori (H. pylori) is a highly prevalent chronic
infection with a worldwide prevalence of nearly 50% and U.S.
prevalence of 30–40% (1, 2). H. pylori is well recognized as
a major factor in the pathogenesis of chronic gastritis, peptic
ulcer disease, and gastric malignancies (3–5). Consequently,
there has been great emphasis placed on the successful erad-
ication of this infection. Multiple first-line treatments have
been employed, and the most successful regimens achieve
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eradication rates ranging from 75% to 90% (3). Unfortu-
nately, patients with persistent H. pylori infection despite a
course of antibiotic therapy are more challenging to success-
fully cure of their infection (6).
A number of salvage regimens have been evaluated in
patients with persistent H. pylori infection. Currently, the
internationally recommended salvage therapy for persistent
H. pylori infection is a bismuth-based quadruple drug reg-
imen consisting of a proton pump inhibitor, bismuth salt,
metronidazole, and tetracycline for a minimum of 7 days (7).
The advantages of this regimen include wide availability, low
cost, and reasonably good efficacy in the salvage setting rel-
ative to other regimens. However, a recent pooled analysis of
trials which evaluated this regimen as salvage therapy for per-
sistent H. pylori infection demonstrated a treatment failure
rate of nearly 25% (6). In addition to the marginal eradication
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rate, other concerns which have been raised regarding
bismuth-based quadruple therapy include the complexity of
the regimen and the frequency of associated side effects
(8–11).
Levofloxacin, a levorotatory isomer of ofloxacin, is a flu-
oroquinolone with antibacterial activity against a wide range
of gram-positive and gram-negative organisms (12) includ-
ing in vitro activity against H. pylori (13). This antibacterial
activity coupled with its excellent bioavailability and ease of
dosing (single daily dosing and co-ingestion with food) make
levofloxacin an attractive therapy for H. pylori infection (14,
15). Recently, levofloxacin-based regimens have been stud-
ied as salvage therapy for persistent H. pylori infection. In
general, the available clinical trials have involved small num-
bers of patients and demonstrated variable eradication rates,
ranging from 63% to 94% (16, 17).
We systematically reviewed all randomized controlled tri-
als (RCTs) which compared the eradication rates and tol-
erability of levofloxacin-based triple therapy to bismuth-
based quadruple salvage therapy in the treatment of persistent
H. pylori infection. By summarizing the data from RCTs,
meta-analysis will provide greater statistical power and a
more precise estimate of eradication rates with these sal-
vage regimens in patients with persistent H. pylori infection.
This analysis will also provide a more precise comparison
of the frequency and severity of side effects associated with
each salvage regimen. We also systematically reviewed all
prospective trials (randomized or nonrandomized) evaluat-
ing levofloxacin-based triple therapy as a salvage therapy to
more precisely estimate the impact of treatment duration and
levofloxacin dosing schedule on eradication rates.
METHODS
Literature Search
The following strategy was employed to identify relevant
trials. Separate computer-assisted searches were performed
utilizing the PUBMED, EMBASE, and EBM Review of
Cochrane Central Register of controlled trials. Each search
was performed on all English language articles through April
2005 using the exploded medical subject heading terms “lev-
ofloxacin” and “H. pylori.” Additionally, all abstracts pre-
sented at the Digestive Disease Week from 2002 to 2005,
United European Gastroenterology Week meetings from
2002 to 2004, and European Helicobacter Study Group’s
yearly workshop from 2000 to 2004 were manually searched.
Finally, manual searches of reference lists from identified rel-
evant papers were performed to identify any additional stud-
ies that may have been missed using the above-mentioned
searches.
Study Selection Criteria
The titles and abstracts of all citations identified by the liter-
ature search were reviewed. Selection criteria were then ap-
plied to all potentially relevant studies. The selection criteria
for inclusion in the meta-analysis were (a) RCT with parallel
group design comparing levofloxacin-based triple therapy to
bismuth-based quadruple therapy; (b) a levofloxacin-based
triple therapy that included amoxicillin and a PPI; (c) con-
firmation of treatment failure to at least one prior course of
standard triple therapy (based on urea breath testing or gas-
tric mucosal biopsy for histology and/or culture and/or rapid
urea testing); (d) intention-to-treat analysis; and (e) confir-
mation of infection eradication at least 4 wk after completion
of treatment (based on urea breath testing or gastric mucosal
biopsy for histology or culture).
A broader set of selection criteria was then applied to the
same collection of potentially relevant studies for inclusion in
the pooled analysis which would assess the effect of duration
of therapy and levofloxacin dosing schedule on eradication
rates. The criteria for inclusion were (a) a prospective trial
assessing the efficacy of a levofloxacin-based triple therapy
as a salvage treatment for persistent H. pylori infection; (b)
a levofloxacin-based triple therapy that included amoxicillin
and a PPI; (c) confirmation of treatment failure to at least one
prior course of standard triple therapy (based on urea breath
testing or gastric mucosal biopsy for histology and/or culture
and/or rapid urease testing); (d) intention-to-treat analysis;
and (e) confirmation of infection eradication at least 4 wk
after completion of treatment (based on urea breath testing
or gastric mucosal biopsy for histology or culture).
Data Extraction
Two investigators (R.S and W.C.) extracted the data from the
studies meeting the selection criteria. Data were extracted
concerning (a) study design; (b) number of patients enrolled
in the study; (c) number of patients in each treatment arm;
(d) testing used to confirm persistent infection prior to study
enrollment; (e) drug regimen, including specific doses and
treatment duration; (f ) testing used to confirm eradication,
including timing of such testing after completion of treat-
ment; (g) number of patients in which H. pylori infection
was successfully eradicated (either directly provided or cal-
culated given the intention-to-treat and per protocol analy-
ses); and (h) number of patients with side effects and number
of patients discontinuing therapy due to side effects. There
was greater than 95% agreement in data extraction between
the two investigators.
Statistical Analysis
The primary study outcomes for the meta-analysis were (a)
the eradication rate of levofloxacin-based triple therapy com-
pared to bismuth-based quadruple therapy; (b) incidence
of adverse events in the levofloxacin-based therapy versus
bismuth-based quadruple therapy; and (c) incidence of ther-
apy discontinuation due to adverse events in the levofloxacin-
based therapy versus bismuth-based quadruple therapy. A
pooled analysis was also planned to assess several secondary
outcomes for levofloxacin-based triple therapy, including (a)
eradication rates with 7 days of therapy versus 10 days of
therapy; (b) eradication rates with levofloxacin 250 mg b.i.d.
versus 500 mg q.d.
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Following data extraction, eradication rates from intention-
to-treat analyses were entered into Stata 8.2 (Stata, College
Station, TX) and StatXact 5.0 software programs for the per-
formance of meta-analysis. In summarizing the data from
these comparative trials, risk ratio (RR) was used as the mea-
sure of association, and summary relative RRs along with
its 95% CI were calculated based on a fixed-effects model
using the methods of DerSimonian and Laird (18). A test of
heterogeneity was also performed to establish if any clinical,
methodological, or statistical variability existed among the
studies used in meta-analysis. If significant heterogeneity ex-
ists, it would be inappropriate to combine the data for further
analysis. Statistical significance for the test of heterogeneity
was set at 0.10. The same method of meta-analysis was ap-
plied to the incidence of adverse events and discontinuation
of therapy due to adverse events for the RCTs.
Eradication rates by intention-to-treat analyses from all
prospective studies, randomized and nonrandomized, were
also pooled. A summary eradication rate and a 95% CI were
calculated for four subgroups: 10-day course of levofloxacin
therapy; 7-day course of levofloxacin therapy; levofloxacin
250 mg b.i.d. regimen; and levofloxacin 500 mg q.d. reg-
imen. Summary estimates were obtained even if significant
heterogeneity between individual trial results was present be-
cause the goal of this analysis was to make between-group
comparisons based on the summary estimates. We then as-
sessed if the summary rate in one subgroup was included in
the 95% CI of the other subgroup. If the summary rate of one
group was not included in the 95% CI of the other subgroup,
the difference in the rates between the two subgroups was
considered statistically significant. Two additional methods
including a meta-regression and calculation of an odds ratio
were performed to confirm the results of the between-group
comparisons based on the summary estimates.
RESULTS
Search Results
The results of the search strategy are summarized in Figure 1.
Following a thorough review of the titles, abstracts, and
manuscripts of the potentially relevant studies, three pub-
lished manuscripts (16, 17, 19) and three abstracts (7, 20–
22) met inclusion criteria for the meta-analysis comparing
eradication rates and tolerability of levofloxacin-based triple
therapy versus bismuth-based quadruple salvage therapy for
persistent H. pylori infection. Characteristics of the six stud-
ies used in the meta-analysis are summarized in Table 1.
Five additional prospective studies met inclusion criteria
for the pooled analysis assessing effects of duration of therapy
on eradication rates. There were three studies published in full
manuscript form (10, 23, 24) and two abstracts (25, 26). Eight
of the 11studies in the pooled analysis assessed levofloxacin
dosages of 250 mg b.i.d. or 500 mg q.d. The study by Wong et
al. (21) and Cammarota et al. (10) administered levofloxacin
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Figure 1. Results of search strategy.
(23) administered a dose of 200 mg b.i.d. Characteristics of
the additional five studies used in the pooled analyses are
summarized in Table 2.
Levofloxacin-Based Triple Therapy versus Bismuth-Based
Quadruple Therapy for Persistent H. Pylori
Six trials directly compared a levofloxacin-based triple ther-
apy versus bismuth-based quadruple salvage therapy (16, 17,
19–22). The results of these studies are summarized in Table
3. A meta-analysis of the eradication rates with intention-to-
treat analyses demonstrated superiority of the levofloxacin-
based triple therapy to bismuth-based quadruple therapy with
a relative RR of 1.18 (95% CI: 1.08–1.29) (Fig. 2). However,
there was significant heterogeneity present in this analysis
(p = 0.000). This heterogeneity suggested that significant
methodological differences existed among the studies mak-
ing it inappropriate to combine them.
Analysis of individual RCTs revealed a clear difference
in eradication rates between 10-day courses of levofloxacin-
based triple therapy and 7-day courses of levofloxacin-
based triple therapy. Therefore, a post hoc meta-analysis was
performed comparing the 10-day courses of levofloxacin-
based treatment to bismuth-based quadruple salvage therapy
demonstrating superiority of the levofloxacin-based therapy
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Table 1. Characteristics of Studies Used in Meta-Analysis (as Well as Pooled-Analysis)
Test Testing
Study Study Patient Prior Confirming Confirming
(Country) Design Enrollment Treatment Infection Treatment Regimen Eradication





C 500 mg b.i.d. +
A 1 gm b.i.d. +
R 20 mg b.i.d.
UBT & Bx for
histology
L 500 mg q.d. + A 1 gm b.i.d.
+ R 20 mg b.i.d. × 10 d
L 500 mg q.d. + Tn 500 mg
b.i.d. + R 20 mg b.i.d. × 10 d
B 120 mg q.i.d. + T 500 mg
q.i.d. +M 500 mg t.i.d. +R
20 mg b.i.d. × 7 d
B 120 mg q.i.d. +T 500 mg
q.i.d. + M 500 mg t.i.d. + R
20 mg b.i.d. × 10 d
UBT 6 wk after
therapy





C 500 mg b.i.d. +
A 1 gm b.i.d. +
O 20 mg b.i.d.
× 7 d
UBT RBC 400 mg b.i.d. + A 1 gm
b.i.d. + Tn 500 mg b.i.d. × 7
d
L 500 mg q.d. + A 1 gm
b.i.d. + P 40 mg b.i.d. × 7 d
B 240 mg b.i.d. + T 500 mg
q.i.d. + M 500 mg b.i.d. + P













UBT & Bx for
histology
L 250 mg b.i.d. + A 1 gm b.i.d.
+ P 40 mg b.i.d. × 10 d
B 240 mg b.i.d. + T 250 mg
q.i.d. + M 500 mg b.i.d. + O
20 mg b.i.d. × 7 d
UBT 4 wk after
therapy






Not stated RUT & Bx for
culture and
histology
L 500 mg b.i.d. + A 1 gm b.i.d.
+ La 30 mg b.i.d. × 7 d
B 120 mg q.i.d. + T 500 mg
q.i.d. + M 400 mg t.i.d. + La
30 mg b.i.d. × 7 d
UBT 6 wk after
therapy






C 500 mg b.i.d. +
A 1 gm b.i.d. +
E 20 mg b.i.d.
UBT L 500 mg q.d. + A 1 gm b.i.d.
+ E 40 mg q.d. × 10 d
L 500 mg q.d. + Az 500 mg
q.d. + E 40 mg q.d. × 10 d
B 120 mg q.i.d. + T 500 mg
q.i.d. + M 500 mg t.i.d. + R
20 mg b.i.d. × 7 d
UBT 6 wk after
therapy






C 500 mg b.i.d. +
A 1 gm b.i.d. +
R 20 mg b.i.d.
UBT L 500 mg q.d. + A 1 gm b.i.d.
+ R 20 mg b.i.d. × 10 d
L 500 mg q.d. + A 1 gm
b.i.d. + R 20 mg b.i.d. × 7 d
B 120 mg q.i.d. + T 500 mg
q.i.d. + M 500 mg t.i.d. + R
20 mg b.i.d. × 7 d
UBT 6 wk after
therapy
RCT = randomized controlled trial; UBT = urea breath test; RUT = rapid urea test; Bx = mucosal biopsy; L = levofloxacin; A = amoxicillin; R = rabeprazole; Tn =
tinidazole; B = bismuth; C = clarithromycin; T = tetracycline; M = metronidazole; RBC = ranitidine bismuth citrate; P = pantoprazole; O = omeprazole; E = esomeprazole;
Az =azithromycin; d = days.
(RR = 1.41 [95% CI: 1.25–1.59]) (Fig. 3). This meta-analysis
did not demonstrate statistically significant heterogeneity
(p = 0.269). An overall eradication rate was also calculated
by combining the results from these four RCTs revealing 87%
(95% CI: 79–96%) eradication rate for the levofloxacin-based
therapy compared to 60% (95% CI: 45–74%) eradication rate
for bismuth-based quadruple therapy.
Adverse events were less common with 10-day levofl-
oxacin-based triple therapy versus bismuth-based quadru-
ple salvage therapy. Three of the four RCTs reported the
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Table 2. Characteristics of Studies Used Only in Pooled Analysis
Test Testing
Study Study Patient Prior Confirming Treatment Confirming





33 C 200 or 400 mg
b.i.d. + A 750
mg b.i.d. + La
30 mg b.i.d.
Bx for culture and
histology
L 200 mg b.i.d.
+ A 1 gm
b.i.d. +La 30
mg b.i.d. × 7
d





36 PPI + C + A ×
7 d or PPI +
A + M × 7 d
RUT & Bx for
histology
L 250 mg b.i.d.
+ A 1 gm
b.i.d. + R 20
mg b.i.d. × 10
d
UBT at 6–8 wk





94 PPI + C + A ×
7 d or PPI +
A + M × 7 d
Bx for culture L 500 mg b.i.d.
+ A 1 gm
b.i.d. + O 20
mg b.i.d. × 7
d
UBT at 8 wk








C + A + PPI
RUT, Bx for culture
and histology
(two of three)
L 250 mg b.i.d.
+ A 1 gm
b.i.d. +E 40
mg b.i.d. × 10
d
Bx at 4–6 wk








C + A + O
UBT L 500 mg q.d. +
A 1 gm b.i.d.
+ O 20 mg
b.i.d. × 7 d
UBT at 4–6 wk
Abbreviations: RCT = randomized controlled trial; UBT = urea breath test; RUT = rapid urea test; Bx = mucosal biopsy; L = levofloxacin; A = amoxicillin; C = clarithromycin;
R = rabeprazole; Tn = tinidazole; B = bismuth; T = tetracycline; M = metronidazole; P + pantoprazole; O = omeprazole; La = lansoprazole; E = esomeprazole; PPI = proton
pump inhibitor; d = days.
frequency of adverse events with levofloxacin-based triple
therapy (18.1% or 26/144) and bismuth-based quadruple sal-
vage therapy (32.5% or 49/151) (17, 19, 20). Meta-analysis
revealed a significant difference in the frequency of adverse
events, which favored levofloxacin-based triple therapy (RR
= 0.51 [95% CI = 0.34–0.75]) (Fig. 4). This meta-analysis
Table 3. Results of RCTs
Patients with Number of Number of Patients
H. pylori Eradication Patients Discontinuing
Patient Successfully Rate with Side Therapy Due to
Study Treatment Arm Enrolled Eradicated (95% CI) Effects Side Effects
Ten-day course of levofloxacin therapy
Nista et al. (17) Levofloxacin triple therapy 70 66 94% 7 0
Quadruple therapy 70 44 63% 15 5
Nista et al. (20) Levofloxacin triple therapy 30 26 87% 8 0
Quadruple therapy 35 25 71% 21 4
Bilardi et al. (19) Levofloxacin triple therapy 44 31 70% (53–87%) 11 1
Quadruple therapy 46 17 37% (23–47%) 13 1
Nista et al. (22) Levofloxacin triple therapy 46 42 91% Not reported 0
Quadruple therapy 50 34 68% Not reported 4
Seven-day course of levofloxacin therapy
Perri et al. (16) Levofloxacin triple therapy 60 38 63% (51–76%) 3 1
Quadruple therapy 60 50 83% (74–93%) 17 3
Wong et al. (21) Levofloxacin triple therapy 33 21 64% Not reported Not reported
Quadruple therapy 30 22 73% Not reported Not reported
Nista et al. (22) Levofloxacin triple therapy 50 37 74% Not reported 0
Quadruple therapy 50 34 68% Not reported 4
did not demonstrate statistically significant heterogeneity
(p = 0.12).
The four RCTs demonstrated that adverse events were
less likely to prompt discontinuation of therapy with 10 days
of levofloxacin-based triple therapy (0.5% or 1/190) versus
bismuth-based quadruple therapy (6.6% or 14/211) (17, 19,
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Figure 2. Relative risk of H. pylori eradication with levofloxacin-
based triple therapy compared to bismuth-based quadruple therapy
Relative RR of individual studies (95% CI): Wong = 0.87 (0.62,
1.21); Perri = 0.76 (0.61, 0.95); Nista3 = 1.09 (0.85, 1.40); Nista1
= 1.50 (1.24, 1.81); Nista2 = 1.21 (0.94, 1.56); Bilardi = 1.91 (1.25,
2.91); Nista3 = 1.34 (1.09, 1.66).
20, 22). A meta-analysis revealed a significant difference in
the discontinuation of therapy due to adverse events, which
favored levofloxacin-based triple therapy (RR = 0.30 [95%
CI = 0.10–0.89]) (Fig. 5). This analysis did not demonstrate
statistically significant heterogeneity (p = 0.61).
Effect of Levofloxacin Dosage and Treatment Duration
on Efficacy of Therapy
Eleven prospective trials, randomized and nonrandomized,
totaling 12 treatment arms and 547 patients had intention-
to-treat eradication rates comparing the efficacy of 7 days
of levofloxacin-based triple therapy with that of 10 days of
therapy. Pooled analysis demonstrated clear superiority of the
Figure 3. Relative risk of H. pylori eradication with 10 days of levofloxacin-based triple therapy compared to 7 days of bismuth-based
quadruple therapy Relative RR of individual studies (95% CI): Nista1 = 1.50 (1.24, 1.81); Nista2 = 1.21 (0.94, 1.56); Bilardi = 1.91 (1.25,
2.91); Nista3 = 1.34 (1.09, 1.66).
10-day course over the 7-day course of therapy with an erad-
ication rate of 87% (95% CI of 82–92%) versus 68% (95%
CI of 62–74%), respectively. This conclusion was confirmed
with a meta-regression analysis as well as a calculation of an
odds ratio in favor of the 10-day course of therapy.
Eight prospective trials, randomized and nonrandomized,
totaling 9 treatment arms and 477 patients had intention-to-
treat eradication rates comparing the efficacy of 250 mg b.i.d.
of levofloxacin with that of 500 mg q.d. of levofloxacin. The
pooled analysis demonstrated no difference in 250 mg b.i.d.
dosing with that of 500 mg q.d. dosing with eradication rates
of 84% (95% CI of 78–89%) versus 81% (95% CI of 66–
97%), respectively. The meta-regression analysis also con-
firmed that no difference in eradication rates existed between
the different dosing regimens of levofloxacin.
DISCUSSION
In general, the most important predictors of H. pylori treat-
ment failure include pretreatment antibiotic resistance (27)
and patient noncompliance with the medical regimen (11).
The current background resistance rates of H. pylori in the
United States are 37% for metronidazole and 10% for clar-
ithromycin (28). Conversely, resistance to tetracycline and
amoxicillin remains a rare occurrence (29). In patients with
persistent H. pylori infection, the corresponding rates are typ-
ically even higher and greatly influenced by the constituents
of the failed initial treatment regimen (30). It is likely that
metronidazole resistance plays a role in the significant fail-
ure rate of bismuth-based quadruple salvage therapy.
Compliance with any medical therapy is influenced by the
complexity of the dosing regimen (number of pills and fre-
quency) and the frequency and severity of associated side
494 Saad et al.
Figure 4. Relative risk for side effects of therapy with 10 days of
levofloxacin-based triple therapy versus 7 days of bismuth-based
quadruple therapy Relative RR of individual studies (95% CI): Perri
= 0.18 (0.05, 0.57); Nista1 = 0.47 (0.20, 1.07); Nista2 = 0.44 (0.23,
0.85); Bilardi = 0.88 (0.44, 1.76).
effects. Disadvantages of bismuth-based quadruple therapy
include the large daily pill count (potentially exceeding 18
pills), dosing frequency (typically four times daily), and fre-
quent side effects (occurring in >50% of patients in some
studies (8–10)). Related to these drawbacks, more effective,
simpler, and better tolerated salvage regimens for persistent
H. pylori infection are needed.
Levofloxacin-based triple therapy offers a number of ad-
vantages over bismuth-based quadruple therapy. First and
foremost, a 10-day course of levofloxacin-based triple therapy
appears to be more effective at eradicating persistent H. pylori
infection than bismuth-based quadruple therapy. Our results
Figure 5. Relative risk of discontinuation of therapy due to side
effects with 10 day levofloxacin-based therapy versus 7 days of
bismuth-based quadruple therapy Relative RR of individual studies
(95% CI): Perri = 0.43 (0.07, 2.81); Nista1 = 0.09 (0.01, 1.61);
Nista2 = 0.13 (0.01, 2.31); Bilardi = 1.04 (0.11, 9.67); Nista3 =
0.12 (0.01, 2.18).
have also shown better overall tolerance of the levofloxacin-
based triple therapy compared to bismuth-based quadruple
therapy. In combination with the very low rate of levofloxacin
and amoxicillin resistance among H. pylori strains, we spec-
ulate that the improved tolerability of this regimen leads to
improved compliance and ultimately, greater eradication rates
compared to bismuth-based quadruple therapy.
This study also provides valuable information regarding
the optimal means of administering this regimen in the sal-
vage setting. A 10-day course of levofloxacin-based triple
therapy proved superior to a 7-day course of therapy. Al-
though the increased duration of therapy could theoretically
negatively impact compliance, this concern appears to be
more than offset by the improved tolerability of this regi-
men (22). Additionally, our study did not demonstrate any
benefit of twice daily dosing versus once daily dosing of lev-
ofloxacin. In the hopes of improving compliance, it would
then seem reasonable to use a 500 mg q.d. over the 250 mg
b.i.d. dosing schedule. There is some emerging evidence to
suggest that levofloxacin dosing greater than 500 mg q.d.
provides higher tissue concentrations which may lead to more
effective treatment outcomes in respiratory infections (31).
However, for H. pylori infection, there is little to no evidence
that increasing the dose of levofloxacin results in greater erad-
ication rates. One small study using levofloxacin at a dosage
of 500 mg b.i.d. for 7 days actually demonstrated an erad-
ication rate of only 64% (21). However, this study has not
been published as a full manuscript and included a signif-
icant number of patients who had failed multiple previous
courses of eradication therapy (eradication rates were 54%
for those failing >1 course of therapy versus 79% in those
failing only one course of therapy). Whether or not improved
eradication rates can be achieved with the use of a higher
dose of levofloxacin for longer periods of time remains to be
determined.
Several methodological weaknesses may limit the valid-
ity and generalizability of this meta-analysis. Initially, the
findings of the meta-analysis demonstrated a superiority of
levofloxacin-based triple therapy over bismuth-based quadru-
ple salvage therapy. However, this analysis also demonstrated
statistically significant heterogeneity calling into question
the validity of combining these results into a meta-analysis.
Analysis of individual RCTs indicated that 7-day versus
10-day treatment duration led to markedly different eradi-
cation rates, which likely contributed to the heterogeneity
seen in the initial meta-analysis. This led to the performance
of a post hoc meta-analysis comparing only studies utiliz-
ing a 10-day course of levofloxacin-based triple therapy to 7
days of bismuth-based quadruple salvage therapy. This cor-
rected the heterogeneity and still demonstrated superiority
of levofloxacin-based therapy. There is also the theoretical
concern for publication bias. We considered the creation of
a funnel plot to determine if we could identify evidence of
publication bias. However, given the small number of studies
included in this review, there were not enough data points to
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perform a funnel plot with any interpretative value. We there-
fore created scatter plots evaluating eradication rates against
year of publication and eradication rates against sample size
from the studies used in this systematic review. Acknowl-
edging the small number of studies included, we found no
trend to suggest significant publication bias. Lastly, there are
no studies involving patients from North America. The stud-
ies included were conducted in Italy, China, and Japan. It is
well established that antibiotic resistance profiles of H. py-
lori vary among different geographical regions (32). Such
resistance profiles are likely to significantly impact on the ef-
ficacy of both bismuth-based quadruple salvage therapy and
levofloxacin-based triple therapy (29), and thus, may limit
generalizability of these results to European or North Amer-
ican populations.
Although there is little data addressing the prevalence of
levofloxacin resistance among H. pylori strains, the reports
available suggest such resistance to be relatively uncommon
(33). There is evidence to suggest that quinolone resistance
is easily acquired, particularly in regions with high use (34).
This may be a concern in countries such as the United States
where quinolones are used to treat a variety of common infec-
tions affecting the urinary tract, respiratory tract, and skin.
Though we were not able to identify data on levofloxacin
resistance among H. pylori strains from the United States,
a recent abstract from Canada reported a levofloxacin re-
sistance rate of 6–8% (33). A particularly attractive feature
of this regimen is its effectiveness in patients infected with
strains of H. pylori resistant to clarithromycin and/or metron-
idazole. Gatta et al. demonstrated excellent eradication rates
of 87% in 107 patients, 80% of which had H. pylori resis-
tant to both clarithromycin and metronidazole (25). Some
have suggested that levofloxacin-based salvage therapy be
reserved for patients with documented or suspected resis-
tance (29). Unfortunately, this recommendation is not prac-
tical in the United States where testing for antimicrobial
resistance is neither recommended nor readily available. It
makes sense to suggest that bismuth-based quadruple therapy
be considered in patients who have not been previously ex-
posed to regimens containing tetracycline or metronidazole.
Levofloxacin-based triple therapy would be reserved for those
that had been treated with a regimen containing tetracycline or
metronidazole or could not tolerate bismuth-based quadruple
therapy.
In conclusion, our analysis demonstrates that a 10-day
course of levofloxacin-based triple therapy is more effec-
tive and better tolerated than 7 days of bismuth-based
quadruple therapy for the treatment of persistent H. py-
lori infection. We recommend that a randomized, controlled
trial comparing levofloxacin-based triple and bismuth-based
quadruple therapy be perfomed in a U.S. population with
persistent H. pylori infection to confirm the results of our
meta-analysis. However, on the basis of these results, we pro-
pose that levofloxacin-based triple therapy provides an effec-
tive alternative salvage regimen to bismuth-based quadruple
therapy.
STUDY HIGHLIGHTS
What is Current Knowledge Eradication failure in the treatment of H. pylori infec-
tion is primarily due to antimicrobial resistance and
patient non-compliance Salvage therapies for persistent H. pylori infection are
associated with higher failure rates than primary ther-
apies The most commonly recommended salvage therapy
for persistent H. pylori infection is at least 7 days of
bismuth-based quadruple therapy Levofloxacin-based triple therapy is a recently de-
scribed salvage regimen for persistent H. pylori infec-
tion
What is New Here A 10 day course of levofloxacin-based triple therapy
provided a higher eradication rate than a 7 day course
of bismuth-based quadruple therapy in patients with
persistent H. pylori infection Levofloxacin-based triple therapy was better tolerated
and associated with a lower likelihood of discontinua-
tion than bismuth-based quadruple therapy Levofloxacin 500mg given once daily and levofloxacin
250mg given twice daily yield equivalent eradication
rates for persistent H. pylori infection
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